E
43.74
0.13 (0.30%)
| Previous Close | 43.61 |
| Open | 43.80 |
| Volume | 1,867,850 |
| Avg. Volume (3M) | 2,596,840 |
| Market Cap | 11,774,918,656 |
| Price / Earnings (TTM) | 18.38 |
| Price / Earnings (Forward) | 15.31 |
| Price / Sales | 5.54 |
| Price / Book | 5.49 |
| 52 Weeks Range | |
| Earnings Date | 10 Feb 2026 |
| Profit Margin | 27.99% |
| Operating Margin (TTM) | 33.64% |
| Diluted EPS (TTM) | 2.19 |
| Quarterly Revenue Growth (YOY) | 30.60% |
| Quarterly Earnings Growth (YOY) | 327.70% |
| Total Debt/Equity (MRQ) | 8.78% |
| Current Ratio (MRQ) | 3.50 |
| Operating Cash Flow (TTM) | 842.59 M |
| Levered Free Cash Flow (TTM) | 559.13 M |
| Return on Assets (TTM) | 18.05% |
| Return on Equity (TTM) | 30.22% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Exelixis, Inc. | Bullish | Bullish |
AIStockmoo Score
1.6
| Analyst Consensus | 1.5 |
| Insider Activity | 3.0 |
| Price Volatility | -0.5 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 0.5 |
| Average | 1.60 |
|
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 2.20% |
| % Held by Institutions | 93.99% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 52.00 (HC Wainwright & Co., 18.88%) | Buy |
| Median | 48.00 (9.74%) | |
| Low | 40.00 (UBS, -8.55%) | Hold |
| Average | 46.40 (6.08%) | |
| Total | 2 Buy, 3 Hold | |
| Avg. Price @ Call | 41.89 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 27 Jan 2026 | 52.00 (18.88%) | Buy | 43.74 |
| 08 Jan 2026 | 52.00 (18.88%) | Buy | 44.15 | |
| Morgan Stanley | 08 Jan 2026 | 48.00 (9.74%) | Hold | 44.15 |
| 05 Nov 2025 | 45.00 (2.88%) | Buy | 40.37 | |
| UBS | 06 Nov 2025 | 40.00 (-8.55%) | Hold | 40.80 |
| Barclays | 05 Nov 2025 | 41.00 (-6.26%) | Hold | 40.37 |
| TD Cowen | 05 Nov 2025 | 51.00 (16.60%) | Buy | 40.37 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AFTAB DANA | 45.44 | 45.44 | 92,324 | 4,195,203 |
| HALEY PATRICK J. | 45.44 | 45.44 | 107,176 | 4,870,077 |
| MORRISSEY MICHAEL | 45.44 | 45.44 | 408,549 | 18,564,467 |
| SENNER CHRISTOPHER J. | 45.44 | 45.44 | 109,015 | 4,953,642 |
| Aggregate Net Quantity | 717,064 | |||
| Aggregate Net Value ($) | 32,583,388 | |||
| Aggregate Avg. Buy ($) | 45.44 | |||
| Aggregate Avg. Sell ($) | 45.44 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| SENNER CHRISTOPHER J. | Officer | 15 Jan 2026 | Acquired (+) | 149,474 | 45.44 | 6,792,099 |
| SENNER CHRISTOPHER J. | Officer | 15 Jan 2026 | Disposed (-) | 40,459 | 45.44 | 1,838,457 |
| HALEY PATRICK J. | Officer | 15 Jan 2026 | Acquired (+) | 139,508 | 45.44 | 6,339,244 |
| HALEY PATRICK J. | Officer | 15 Jan 2026 | Disposed (-) | 32,332 | 45.44 | 1,469,166 |
| AFTAB DANA | Officer | 15 Jan 2026 | Acquired (+) | 119,578 | 45.44 | 5,433,624 |
| AFTAB DANA | Officer | 15 Jan 2026 | Disposed (-) | 27,254 | 45.44 | 1,238,422 |
| MORRISSEY MICHAEL | Officer | 15 Jan 2026 | Acquired (+) | 548,073 | 45.44 | 24,904,437 |
| MORRISSEY MICHAEL | Officer | 15 Jan 2026 | Disposed (-) | 139,524 | 45.44 | 6,339,971 |
| Date | Type | Details |
|---|---|---|
| 27 Jan 2026 | Announcement | Exelixis to Release Fourth Quarter and Fiscal Year 2025 Financial Results on Tuesday, February 10, 2026 |
| 11 Jan 2026 | Announcement | Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 |
| 07 Jan 2026 | Announcement | Exelixis and Natera to Collaborate on STELLAR-316, a Phase 3 Pivotal Trial of Zanzalintinib for Patients with Colorectal Cancer |
| 06 Jan 2026 | Announcement | Exelixis to Present at the J.P. Morgan 2026 Healthcare Conference on January 12, 2026 |
| 03 Dec 2025 | Announcement | Exelixis to Webcast Virtual 2025 Research & Development (R&D) Day on Wednesday, December 10, 2025 |
| 06 Nov 2025 | Announcement | Exelixis to Webcast Fireside Chats as Part of Upcoming Investor Conferences in November |
| 04 Nov 2025 | Announcement | Exelixis Announces Third Quarter 2025 Financial Results and Provides Corporate Update |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |